Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.60 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | SHBG | P04278 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.60 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | PGR | P06401 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94105 | 0.88 | HIF1A (0.63) | HSD17B10NR3C1SERPINA6ALDH1A1LMNA | |
| SCHEMBL28318620 | 0.85 | HIF1A (0.60) | HSD17B10NR3C1SERPINA6ALDH1A1LMNA | |
| SCHEMBL2330386 | 0.85 | NR3C1 (0.59) | HSD17B10NR3C1SERPINA6ALDH1A1LMNA | |
| SCHEMBL8061818 | 0.85 | HIF1A (0.59) | HSD17B10NR3C1SERPINA6ALDH1A1LMNA | |
| SCHEMBL6370137 | 0.85 | HIF1A (0.59) | HSD17B10NR3C1SERPINA6ALDH1A1LMNA | |
| SCHEMBL8907648 | 0.84 | NR3C1 (0.56) | HSD17B10NR3C1SERPINA6ALDH1A1LMNA | |
| Butyric Acid SCHEMBL28142317 | 0.83 | HIF1A (0.57) | HSD17B10NR3C1SERPINA6ALDH1A1LMNA | |
| SCHEMBL28957729 | 0.83 | HSD17B10 (0.55) | HSD17B10NR3C1SERPINA6ALDH1A1LMNA | |
| SCHEMBL342689 | 0.82 | HSD17B10 (0.71) | HSD17B10NR3C1SERPINA6ALDH1A1LMNA | |
| SCHEMBL8217259 | 0.82 | HSD17B10 (0.71) | HSD17B10NR3C1SERPINA6ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141499-A1 | CARDIOSPHERE-DERIVED CELL (CDC) THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS | CEDARS-SINAI MEDICAL CENTER | 2023-05-11 | — | — | US | claimed |
| WO-2021188899-A1 | CARDIOSPHERE-DERIVED CELL (CDC) THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS | CEDARS-SINAI MEDICAL CENTER (US) | 2021-09-23 | — | — | WO | claimed |
| WO-2023240222-A2 | IMMUNE TOLERANCE INDUCTION TO VIRAL CAPSIDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023178337-A2 | METHODS AND COMPOSITIONS FOR TREATING RBM20 RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178338-A2 | METHODS AND COMPOSITIONS FOR TREATING TMEM43 RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178339-A2 | METHODS AND COMPOSITIONS FOR TREATING TNNT2 RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023108157-A1 | METHODS AND COMPOSITIONS FOR TREATING MYBPC3 RELATED HYPERTROPHIC CARDIOMYOPATHY WITH A VIRAL VECTOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023108159-A1 | METHODS AND COMPOSITIONS FOR TREATING BAG-3 RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023108130-A2 | COMPOSITIONS COMPRISING KOZAK SEQUENCES SELECTED FOR ENHANCED EXPRESSION | AAVANTIBIO, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230141499-A1 | CARDIOSPHERE-DERIVED CELL (CDC) THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS | CEDARS-SINAI MEDICAL CENTER | 2023-05-11 | — | — | US | disclosed |
| WO-2021202599-A2 | ADENO-ASSOCIATED VIRUS BASED COMPOSITIONS AND RELATED METHODS FOR INDUCING HUMORAL IMMUNITY | VALIANT BIOSCIENCES, LLC (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-01-23 | — | — | US | disclosed |
| US-7780982-B2 | Biodegradable hyaluronic acid derivative and biodegradable polymeric micelle composition | INDUSTRIAL TECHNOLOGY RESEARCH INSTITTUTE (TW) | 2010-08-24 | — | — | US | disclosed |
| EP-1538166-B1 | Hyaluronic acid derivative with urethane linkage | IND TECH RES INST (TW) | 2009-02-18 | — | — | EP | disclosed |
| CN-101001842-A | Amido compounds and their use as pharmaceuticals | INCYTE CORP (US) | 2007-07-18 | — | — | CN | disclosed |
| US-20050123505-A1 | Biodegradable hyaluronic acid derivative and biodegradable polymeric micelle composition | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2005-06-09 | — | — | US | disclosed |
| EP-1538166-A1 | Biodegradable hyaluronic acid derivative and composition containing micelles made therefom | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2005-06-08 | — | — | EP | disclosed |
| US-5326761-A | Suspension; sustained release | MERCK SHARP & DOHME-CHIBRET (FR) | 1994-07-05 | — | — | US | disclosed |
| EP-0437368-B1 | Fluid ophthalmic composition based on lipid microparticles containing at least one active principle | MERCK SHARP & DOHME (FR) | 1994-03-02 | — | — | EP | disclosed |
| EP-0437368-A1 | Fluid ophthalmic composition based on lipid microparticles containing at least one active principle | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET (FR) | 1991-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | HSD11B1, HSD11B2, HSD3B1 | HSD17B10 21/4885NR3C1 177/4885SERPINA6 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.